Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CPT-11' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 458 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Palumbo, M; Sissi, C; Gatto, B; Moro, S; Zagotto, G
      Quantitation of camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    2. Zufia, L; Aldaz, A; Giraldez, J
      Separation methods for camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    3. Jung, LL; Zamboni, WC
      Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

      DRUG RESISTANCE UPDATES
    4. Kehrer, DFS; Sparreboom, A; Verweij, J; de Bruijn, P; Nierop, CA; van de Schraaf, J; Ruijgrok, EJ; de Jonge, MJA
      Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients

      CLINICAL CANCER RESEARCH
    5. Minami, H; Fujii, H; Igarashi, T; Itoh, K; Tamanoi, K; Oguma, T; Sasaki, Y
      Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks

      CLINICAL CANCER RESEARCH
    6. Blaney, S; Berg, SL; Pratt, C; Weitman, S; Sullivan, J; Luchtman-Jones, L; Bernstein, M
      A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group Study

      CLINICAL CANCER RESEARCH
    7. Jagasia, MH; Langer, CJ; Johnson, DH; Yunus, F; Rodgers, JS; Schlabach, LL; Cohen, AG; Shyr, Y; Carbone, DP; DeVore, RF
      Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study

      CLINICAL CANCER RESEARCH
    8. Senter, PD; Beam, KS; Mixan, B; Wahl, AF
      Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug

      BIOCONJUGATE CHEMISTRY
    9. Takagi, T; Saotome, T
      Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    10. Platzer, P; Thalhammer, T; Reznicek, G; Hamilton, G; Zhang, RW; Jager, W
      Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver

      INTERNATIONAL JOURNAL OF ONCOLOGY
    11. Agrawal, S; Kandimalla, ER; Yu, D; Hollister, BA; Chen, SF; Dexter, DL; Alford, TL; Hill, B; Bailey, KS; Bono, CP; Knoerzer, DL; Morton, PA
      Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides

      INTERNATIONAL JOURNAL OF ONCOLOGY
    12. Alonso, V; Escudero, P; Zorrilla, M; Isla, MD; Herrero, A; Mayordomo, JI; Martinez-Trufero, J; Saenz, A; Tres, A; Anton, A
      Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer

      EUROPEAN JOURNAL OF CANCER
    13. Guichard, S; Arnould, S; Hennebelle, I; Bugat, R; Canal, P
      Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo

      ANTI-CANCER DRUGS
    14. Yamamoto, W; Verweij, J; de Bruijn, P; de Jonge, MJA; Takano, H; Nishiyama, M; Kurihara, M; Sparreboom, A
      Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

      ANTI-CANCER DRUGS
    15. Kehrer, DFS; Soepenberg, O; Loos, WJ; Verweij, J; Sparreboom, A
      Modulation of camptothecin analogs in the treatment of cancer: a review

      ANTI-CANCER DRUGS
    16. Niitsu, N; Iijima, K; Chizuka, A
      Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study

      ANNALS OF HEMATOLOGY
    17. Rothenberg, ML; Kuhn, JG; Schaaf, LJ; Rodriguez, GI; Eckhardt, SG; Villalona-Calero, MA; Rinaldi, DA; Hammond, LA; Hodges, S; Sharma, A; Elfring, GL; Petit, RG; Locker, PK; Miller, LL; von Hoff, DD
      Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks

      ANNALS OF ONCOLOGY
    18. Oguma, T; Yamada, M; Konno, T; Inukai, K; Nakaoka, M
      High-performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (Exatecan), in mouse plasma

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    19. Sakai, C; Iuchi, T; Ishii, A; Kumagai, K; Takagi, T
      Bacillus cereus brain abscesses occurring in a severely neutropenic patient: Successful treatment with antimicrobial agents, granulocyte colony-stimulating factor and surgical drainage

      INTERNAL MEDICINE
    20. Shimizu, M; Tamura, T; Yamada, Y; Akiyama, Y; Saijo, N; Nishio, K
      CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNAin mouse liver

      JAPANESE JOURNAL OF CANCER RESEARCH
    21. Khayat, D; Gil-Delgado, M; Antoine, EC; Nizri, D; Bastian, G
      The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer

      ONCOLOGY-NEW YORK
    22. Rich, TA; Kirichenko, AV
      Camptothecin schedule and timing of administration with irradiation

      ONCOLOGY-NEW YORK
    23. O'Reilly, EM; Ilson, DH
      Cisplatin and irinotecan in upper gastrointestinal malignancies

      ONCOLOGY-NEW YORK
    24. Lima, CMSR; Sherman, CA; Brescia, FJ; Brunson, CY; Green, MR
      Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer

      ONCOLOGY-NEW YORK
    25. Socinski, MA; Sandler, AB; Miller, LL; Locker, PK; Hanover, CK; Elfring, GL; Israel, VK; Pirotta, N; Natale, RB
      Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer

      JOURNAL OF CLINICAL ONCOLOGY
    26. Becouarn, Y; Gamelin, E; Coudert, B; Negrier, S; Pierga, JY; Raoul, JL; Provencal, J; Rixe, O; Krisch, C; Germa, C; Bekradda, M; Mignard, D; Mousseau, M
      Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    27. Falcone, A; Di Paolo, A; Masi, G; Allegrini, G; Danesi, R; Lencioni, M; Pfanner, E; Comis, S; Del Tacca, M; Conte, P
      Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    28. Arimori, K; Kuroki, N; Kumamoto, A; Tanoue, N; Nakano, M; Kumazawa, E; Tohgo, A; Kikuchi, M
      Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents

      PHARMACEUTICAL RESEARCH
    29. Sloan, JA; Atherton, P; Reid, J; Pilot, HC; Erlichman, C; Schaaf, L
      Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    30. Takeda, K; Negoro, S; Takifuji, N; Nitta, T; Yoshimura, N; Terakawa, K; Fukuoka, M
      Dose escalation study of irinotecan combined with carboplatin for advancednon-small-cell lung cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    31. Sato, A; Kurihara, M; Matsukawa, M; Shimada, K; Yamazaki, T; Nakamachi, M; Koda, T
      Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    32. Guemei, AA; Cottrell, J; Band, R; Hehman, H; Prudhomme, M; Pavlov, MV; Grem, JL; Ismail, AS; Bowen, D; Taylor, RE; Takimoto, CH
      Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    33. Kobayashi, K; Ceryak, S; Matsuzaki, Y; Kudoh, S; Bouscarel, B
      Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

      BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
    34. Mitani, N; Murakami, K; Yamaura, T; Ikeda, T; Saiki, I
      Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma

      CANCER LETTERS
    35. Grifalchi, F; Padovani, A; Romeo, F; Trinca, C; Moscetti, L; Cortesi, E
      Response of metastatic epidermoid anal cancer to single agent irinotecan: A case report

      TUMORI
    36. Gil-Delgado, MA; Antoine, EC; Guinet, F; Bassot, V; Grapin, JP; Benhammonda, A; Adam, R; Castaing, D; Bismuth, H; Khayat, D
      Phase I-II study of irinotecan in combination with mitomycin C in patientswith advanced gastrointestinal cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    37. Gil-Delgado, MA; Guinet, F; Castaing, D; Adam, R; Coeffic, D; Durrani, AKS; Bismuth, H; Khayat, D
      Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    38. Topcu, Z
      DNA topoisomerases as targets for anticancer drugs

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    39. Lansiaux, A; Bras-Goncalves, RA; Rosty, C; Laurent-Puig, P; Poupon, MF; Bailly, C
      Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: Relation with their sensitivity to CTP-11

      ANTICANCER RESEARCH
    40. Vokes, EE; Gordon, GS; Rudin, CM; Mauer, AM; Watson, S; Krauss, S; Arrieta, R; Golomb, HM; Hoffman, PC
      A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer

      INVESTIGATIONAL NEW DRUGS
    41. Pro, B; Lozano, R; Ajani, JA
      Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea

      INVESTIGATIONAL NEW DRUGS
    42. Lima, CMSR; Urbanic, JJ; Lal, A; Kneuper-Hall, R; Brunson, CY; Green, MR
      Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies

      SEMINARS IN ONCOLOGY
    43. Sai, K; Kaniwa, N; Ozawa, S; Sawada, JI
      A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4

      DRUG METABOLISM AND DISPOSITION
    44. Hanioka, N; Ozawa, S; Jinno, H; Ando, M; Saito, Y; Sawada, J
      Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin

      XENOBIOTICA
    45. Kakolyris, S; Souglakos, J; Kouroussis, C; Androulakis, N; Mavroudis, D; Kalbakis, K; Kotsakis, A; Vardakis, N; Koukourakis, M; Romanos, J; Georgoulias, V
      A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer

      ONCOLOGY
    46. Comella, P; Biglietto, M; Casaretti, R; De Luica, L; Avallone, A; Maiorino, L; Di Lullo, L; De Cataldis, G; Rivellini, F; Comella, G
      Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients - A phase I/II study of the Southern Italy Cooperative Oncology Group

      ONCOLOGY
    47. Wadkins, RM; Morton, CL; Weeks, JK; Oliver, L; Wierdl, M; Danks, MK; Potter, PM
      Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases

      MOLECULAR PHARMACOLOGY
    48. Farabos, C; Haaz, MC; Gires, P; Robert, J
      Hepatic extraction, metabolism, and biliary excretion of irinotecan in theisolated perfused rat liver

      JOURNAL OF PHARMACEUTICAL SCIENCES
    49. Takeda, Y; Kobayashi, K; Akiyama, Y; Soma, T; Handa, S; Kudoh, S; Kudo, K
      Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients

      INTERNATIONAL JOURNAL OF CANCER
    50. Iyengar, RV; Pawlik, CA; Krull, EJ; Phelps, DA; Burger, RA; Harris, LC; Potter, PM; Danks, MK
      Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression

      CANCER RESEARCH
    51. Boushey, RP; Yusta, B; Drucker, DJ
      Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor

      CANCER RESEARCH
    52. Wierdl, M; Morton, CL; Weeks, JK; Danks, MK; Harris, LC; Potter, PM
      Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase

      CANCER RESEARCH
    53. Meck, MM; Wierdl, M; Wagner, LM; Burger, RA; Guichard, SM; Krull, EJ; Harris, LC; Potter, PM; Danks, MK
      A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11

      CANCER RESEARCH
    54. Firvida, JL; Irigoyen, A; Vazquez-Estevez, S; Diz, P; Constenla, M; Casal-Rubio, J; Valladares-Ayerbes, M; Castellanos, J; Rodriguez, R; Balcells, M
      Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma

      CANCER
    55. O'Reilly, EM; Stuart, KE; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Raeburn, L; Kemeny, NE; Kelsen, DP; Saltz, LB
      A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma

      CANCER
    56. O'Reilly, EM; Stuart, KE; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Raeburn, L; Kemeny, NE; Kelsen, DP; Saltz, LB
      A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma

      CANCER CYTOPATHOLOGY
    57. Dodds, HM; Rivory, LP
      Comment on a published paper

      BRITISH JOURNAL OF PHARMACOLOGY
    58. Blandizzi, C; De Paolis, B; Colucci, R; Lazzeri, G; Baschiera, F; Del Tacca, M
      Comment on a published paper - Reply to Dobbs & Rivory

      BRITISH JOURNAL OF PHARMACOLOGY
    59. Blandizzi, C; De Paolis, B; Colucci, R; Lazzeri, G; Baschiera, F; Del Tacca, M
      Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan

      BRITISH JOURNAL OF PHARMACOLOGY
    60. Ueoka, H; Tanimoto, M; Kiura, K; Tabata, M; Takigawa, N; Segawa, Y; Takata, I; Eguchi, K; Okimoto, N; Harita, S; Kamei, H; Shibayama, T; Watanabe, Y; Hiraki, S; Harada, M
      Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group

      BRITISH JOURNAL OF CANCER
    61. Boyd, G; Smyth, JF; Jodrell, DI; Cummings, J
      High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells

      ANALYTICAL BIOCHEMISTRY
    62. Pawlik, CA; Iyengar, RV; Krull, EJ; Mason, SE; Khanna, R; Harris, LC; Potter, PM; Danks, MK; Guichard, SM
      Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells toCPT-11

      MOLECULAR THERAPY
    63. Escoriaza, J; Aldaz, A; Castellanos, C; Calvo, E; Giraldez, J
      Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies

      JOURNAL OF CHROMATOGRAPHY B
    64. Oguma, T; Ohshima, Y; Nakaoka, M
      Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the newcamptothecin derivative DX-8951 in human plasma using fluorescence detection

      JOURNAL OF CHROMATOGRAPHY B
    65. Fulco, RA; Costa, C; Germano, MP; Torre, EA; Viscomi, MG; Salimbeni, V; Maisano, R; Giudice, A; Costa, G
      Hepatotoxicity of camptothecin derivatives in a primary culture system of rat hepatocytes

      JOURNAL OF CHEMOTHERAPY
    66. Nikolic-Tomasevic, Z; Jelic, S; Popov, I; Radosavljevic, D
      Irinotecan as second-line treatment in metastatic colorectal cancer: Dilemmas regarding patient selection and toxicity prediction

      JOURNAL OF CHEMOTHERAPY
    67. Ratain, MJ
      Insights into the pharmacokinetics and pharmacodynamics of irinotecan

      CLINICAL CANCER RESEARCH
    68. Ma, MK; Zamboni, WC; Radomski, KM; Furman, WL; Santana, VM; Houghton, PJ; Hanna, SK; Smith, AK; Stewart, CF
      Pharmacokinetics of irinotecan and its metabolites SN-38 and ABC in children with recurrent solid tumors after protracted low-dose irinotecan

      CLINICAL CANCER RESEARCH
    69. Kita, T; Kikuchi, Y; Kudoh, K; Takano, M; Goto, T; Hirata, J; Tode, T; Nagata, I
      Exploratory study of effective chemotherapy to clear cell carcinoma of theovary

      ONCOLOGY REPORTS
    70. Jonsson, E; Dhar, S; Jonsson, B; Nygren, P; Graf, W; Larsson, R
      Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines

      EUROPEAN JOURNAL OF CANCER
    71. Madarnas, Y; Webster, P; Shorter, AM; Bjarnason, GA
      Irinotecan-associated pulmonary toxicity

      ANTI-CANCER DRUGS
    72. Gornet, JM; Azoulay, D; Duclos-Vallee, JC; Goldwasser, F
      Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11

      ANTI-CANCER DRUGS
    73. Hennebelle, I; Terret, C; Chatelut, E; Bugat, R; Canal, P; Guichard, S
      Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity

      ANTI-CANCER DRUGS
    74. Loos, WJ; de Bruijn, P; Verweij, J; Sparreboom, A
      Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

      ANTI-CANCER DRUGS
    75. Gornet, JM; Azoulay, D; Levi, F; Yovine, A; Misset, JL; Goldwasser, F
      Dramatic tumor response of bulky liver metastases following treatment withCPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient

      ANTI-CANCER DRUGS
    76. Fujita, A; Takabatake, H; Tagaki, S; Sekine, K
      Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advancednon-small cell lung cancer

      ANTI-CANCER DRUGS
    77. Kaneki, T; Koizumi, T; Kawashima, A; Tsushima, K; Kubo, K; Fujimoto, K; Honda, T; Akamatsu, T
      Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy

      JOURNAL OF GASTROENTEROLOGY
    78. Kakolyris, S; Kouroussis, C; Kalbakis, K; Mavroudis, D; Souglakos, J; Vardakis, N; Kremos, S; Georgoulias, V
      Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin

      ANNALS OF ONCOLOGY
    79. Goldwasser, F; Gross-Goupil, M; Tigaud, JM; Di Palma, M; Marceau-Suissa, J; Wasserman, E; Yovine, A; Misset, JL; Cvitkovic, E
      Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients

      ANNALS OF ONCOLOGY
    80. Comella, P; De Vita, F; Mancarella, S; De Lucia, L; Biglietto, M; Casaretti, R; Farris, A; Ianniello, GP; Lorusso, V; Avallone, A; Carteni, G; Leo, S; Catalano, G; De Lena, M; Comella, G
      Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II-III randomized trial

      ANNALS OF ONCOLOGY
    81. Saotome, T; Takagi, T; Sakai, C; Kumagai, K; Tamaru, J
      Combination chemotherapy with irinotecan and adriamycin for refractory andrelapsed non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    82. Saita, T; Fujito, H; Mori, M
      Development of ELISAs for irinotecan and its active metabolite SN-38

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    83. Komaki, R; Janjan, NA; Ajani, JA; Lynch, PM; Fairweather, JS; Raijman, I; Blumenshein, GR; Ho, L; Pisters, PWT; Feig, BW; Walsh, GL; Pazdur, R
      Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors

      ONCOLOGY-NEW YORK
    84. Suzuki, A; Tsutomi, Y
      Inductions of fibroblast-like morphology and high growth activity by low-dose CPT-11 in PC12 cells: role of tenascin

      TOXICOLOGY IN VITRO
    85. Adjei, AA; Klein, CE; Kastrissios, H; Goldberg, RM; Alberts, SR; Pitot, HC; Sloan, JA; Reid, JM; Hanson, LJ; Atherton, P; Rubin, J; Erlichman, C
      Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity

      JOURNAL OF CLINICAL ONCOLOGY
    86. Takimoto, CH; Morrison, G; Harold, N; Quinn, M; Monahan, BP; Band, RA; Cottrell, J; Guemei, A; Llorens, V; Hehman, H; Ismail, AS; Flemming, D; Gosky, DM; Hirota, H; Berger, SJ; Berger, NA; Chen, AP; Shapiro, JD; Arbuck, SG; Wright, J; Hamilton, JM; Allegra, CJ; Grem, JL
      Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    87. Boige, V; Raymond, E; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Ducreux, M; Rixe, O; Armand, JP
      Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer

      JOURNAL OF CLINICAL ONCOLOGY
    88. Couteau, C; Risse, ML; Ducreux, M; Lefresne-Soulas, F; Riva, A; Lebecq, A; Ruffie, P; Rougier, P; Lokiec, F; Bruno, R; Armand, JP
      Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors

      JOURNAL OF CLINICAL ONCOLOGY
    89. Rowinsky, EK; Johnson, TR; Geyer, CE; Hammond, LA; Eckhardt, SG; Drengler, R; Smetzer, L; Coyle, J; Rizzo, J; Schwartz, G; Tolcher, A; Von Hoff, DD; De Jager, RL
      DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies

      JOURNAL OF CLINICAL ONCOLOGY
    90. Masuda, N; Negoro, S; Kudoh, S; Sugiura, T; Nakagawa, K; Saka, H; Takada, M; Niitani, H; Fukuoka, M
      Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer

      JOURNAL OF CLINICAL ONCOLOGY
    91. de Jonge, MJA; Sparreboom, A; Planting, AST; van der Burg, MEL; de Boer-Dennert, MM; ter Steeg, J; Jacques, C; Verweij, J
      Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors

      JOURNAL OF CLINICAL ONCOLOGY
    92. de Jonge, MJA; Verweij, J; de Bruijn, P; Brouwer, E; Mathijssen, RHJ; van Alphen, RJ; de Boer-Dennert, MM; Vernillet, L; Jacques, C; Sparreboom, A
      Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin

      JOURNAL OF CLINICAL ONCOLOGY
    93. Denes, A
      The role of irinotecan in non-small cell and small-cell lung cancer

      ONKOLOGIE
    94. Bokemeyer, C
      Irinotecan - Clinical progress in the second-line therapy of advanced colorectal cancer

      ONKOLOGIE
    95. Vanhoefer, U; Achterrath, W; Wilke, H; Seeber, S
      Preclinical evaluation of irinotecan

      ONKOLOGIE
    96. Wilke, H; Vanhoefer, U; Achterrath, W; Stahl, M
      Irinotecan: New results in the combination chemotherapy of colorectal cancer

      ONKOLOGIE
    97. Klautke, G; Fietkau, R
      Irinotecan in radiation oncology

      ONKOLOGIE
    98. Gatzemeier, U
      Options for treatment of lung cancer with irinotecan

      ONKOLOGIE
    99. Kirichenko, AV; Mason, K; Straume, M; Teates, CD; Rich, TA
      Nuclear scintigraphic assessment of intestinal dysfunction after combined treatment with 9-amino-20(S)-camptothecin (9-AC) and irradiation

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    100. Kurita, A; Kado, S; Kaneda, N; Onoue, M; Hashimoto, S; Yokokura, T
      Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats

      CANCER CHEMOTHERAPY AND PHARMACOLOGY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/21 alle ore 08:20:13